OKUR
OnKure Therapeutics, Inc.
Price Chart
Latest Quote
$4.20
+0.10 (+2.44%)
Current Price
| Previous Close | $4.10 |
| Open | $4.16 |
| Day High | $4.22 |
| Day Low | $3.96 |
| Volume | 72,846 |
Stock Information
| Shares Outstanding | 40.40M |
| Total Debt | $409K |
| Cash Equivalents | $192.11M |
| Net Income | $-58.75M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $169.66M |
| EPS (TTM) | $-4.32 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $-22.04M |
| Income | $-58.75M |
| Book/sh | $4.56 |
| Cash/sh | $4.76 |
| Employees | 45 |
Financial Ratios
| Quick Ratio | 13.41 |
| Current Ratio | 13.78 |
| Debt/Eq | 0.22 |
Returns & Margins
| ROA | -25.77% |
| ROE | -42.73% |
Ownership
| Insider Ownership | 10.48% |
| Institutional Ownership | 76.21% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.97 |
| P/B | 0.92 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $20.20 |
Technical Indicators
| SMA20 | $4.37 |
| SMA50 | $4.12 |
| SMA200 | $3.50 |
| RSI | 38.64 |
| ATR | 0.3399 |
| Shares Float | 17.60M |
| Short Float | 2.42% |
| Short Ratio | 1.55 |
| Rel Volume | 0.16 |
Performance History
| Week | -1.87% |
| Month | -1.18% |
| Quarter | -10.06% |
| 6 Months | +31.66% |
| YTD | +41.89% |
| Year | +68.67% |
| 3 Years | -94.12% |
| 5 Years | -95.06% |
| 10 Years | -97.20% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-07-17 | $4.20 | 72,846 |
| 2026-07-16 | $4.10 | 112,900 |
| 2026-07-15 | $4.21 | 79,900 |
| 2026-07-14 | $4.22 | 87,700 |
| 2026-07-13 | $4.11 | 140,700 |
| 2026-07-10 | $4.28 | 193,800 |
| 2026-07-09 | $4.46 | 166,200 |
| 2026-07-08 | $4.48 | 223,700 |
| 2026-07-07 | $4.38 | 370,500 |
| 2026-07-06 | $4.60 | 318,500 |
| 2026-07-02 | $4.58 | 222,300 |
| 2026-07-01 | $4.46 | 276,900 |
| 2026-06-30 | $4.56 | 347,100 |
| 2026-06-29 | $4.50 | 414,100 |
| 2026-06-26 | $4.50 | 2,962,000 |
| 2026-06-25 | $4.22 | 330,600 |
| 2026-06-24 | $4.34 | 627,600 |
| 2026-06-23 | $4.20 | 292,300 |
| 2026-06-22 | $4.44 | 429,800 |
| 2026-06-18 | $4.48 | 1,651,400 |
About OnKure Therapeutics, Inc.
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
đ° Latest News
OnKure Therapeutics Spotlights Allosteric PI3KÎą Drugs as 2027 IND Targets Near
MarketBeat âĸ 2026-07-15T17:02:37Z
TMO Q1 Earnings Preview: Will Life Sciences Solutions Lead Results?
Zacks âĸ 2026-04-16T13:18:00Z
Promising Penny Stocks To Watch In December 2025
Simply Wall St. âĸ 2025-12-09T18:05:18Z
3 Promising Penny Stocks With Market Caps Under $200M
Simply Wall St. âĸ 2025-10-31T18:04:54Z
Companies Like OnKure Therapeutics (NASDAQ:OKUR) Could Be Quite Risky
Simply Wall St. âĸ 2025-08-19T10:57:34Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $8,000 | $300,000 | $0 | - |
| Total Expenses | $62,950,000 | $54,386,000 | $36,934,000 | $29,766,000 |
| Net Non Operating Interest Income Expense | $3,433,000 | $1,713,000 | $1,623,000 | $254,000 |
| Interest Expense Non Operating | $8,000 | $300,000 | $0 | - |
| Operating Expense | $62,950,000 | $54,386,000 | $36,934,000 | $29,766,000 |
| General And Administrative Expense | $14,690,000 | $10,591,000 | $4,819,000 | $3,904,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-59,517,000 | $-52,673,000 | $-35,311,000 | $-29,512,000 |
| Net Interest Income | $3,433,000 | $1,713,000 | $1,623,000 | $254,000 |
| Interest Income | $3,441,000 | $2,013,000 | $1,623,000 | $254,000 |
| Normalized Income | $-59,517,000 | $-52,673,000 | $-35,311,000 | $-29,512,000 |
| Net Income From Continuing And Discontinued Operation | $-59,517,000 | $-52,673,000 | $-35,311,000 | $-29,512,000 |
| Total Operating Income As Reported | $-62,950,000 | $-54,386,000 | $-36,934,000 | $-29,766,000 |
| Net Income Common Stockholders | $-59,517,000 | $-52,673,000 | $-35,311,000 | $-29,512,000 |
| Net Income | $-59,517,000 | $-52,673,000 | $-35,311,000 | $-29,512,000 |
| Net Income Including Noncontrolling Interests | $-59,517,000 | $-52,673,000 | $-35,311,000 | $-29,512,000 |
| Net Income Continuous Operations | $-59,517,000 | $-52,673,000 | $-35,311,000 | $-29,512,000 |
| Pretax Income | $-59,517,000 | $-52,673,000 | $-35,311,000 | $-29,512,000 |
| Interest Income Non Operating | $3,441,000 | $2,013,000 | $1,623,000 | $254,000 |
| Operating Income | $-62,950,000 | $-54,386,000 | $-36,934,000 | $-29,766,000 |
| Per Share | ||||
| Diluted EPS | $-4.40 | $-15.28 | $-2.65 | $-2.21 |
| Basic EPS | $-4.40 | $-15.28 | $-2.65 | $-2.21 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-58,679,000 | $-51,711,000 | $-34,751,000 | $-29,379,000 |
| Reconciled Depreciation | $830,000 | $662,000 | $560,000 | $387,000 |
| EBITDA (Bullshit earnings) | $-58,679,000 | $-51,711,000 | $-34,751,000 | $-29,379,000 |
| EBIT | $-59,509,000 | $-52,373,000 | $-35,311,000 | $-29,766,000 |
| Diluted Average Shares | $13,515,915 | $3,447,071 | $13,339,417 | $13,339,417 |
| Basic Average Shares | $13,515,915 | $3,447,071 | $13,339,417 | $13,339,417 |
| Diluted NI Availto Com Stockholders | $-59,517,000 | $-52,673,000 | $-35,311,000 | $-29,512,000 |
| Research And Development | $48,260,000 | $43,795,000 | $32,115,000 | $25,862,000 |
| Selling General And Administration | $14,690,000 | $10,591,000 | $4,819,000 | $3,904,000 |
| Other Gand A | $14,690,000 | $10,591,000 | $4,819,000 | $3,904,000 |
Fetched: 2026-07-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $56,184,000 | $103,828,000 | $-101,842,000 | $-54,418,000 |
| Total Assets | $62,117,000 | $114,907,000 | $35,734,000 | $15,999,000 |
| Total Non Current Assets | $1,278,000 | $1,904,000 | $1,968,000 | $2,376,000 |
| Other Non Current Assets | $273,000 | $109,000 | $58,000 | $329,000 |
| Current Assets | $60,839,000 | $113,003,000 | $33,766,000 | $13,623,000 |
| Other Current Assets | $1,789,000 | $2,242,000 | $698,000 | $840,000 |
| Cash Cash Equivalents And Short Term Investments | $59,050,000 | $110,761,000 | $29,876,000 | $11,543,000 |
| Cash And Cash Equivalents | $59,050,000 | $110,761,000 | $29,876,000 | $11,543,000 |
| Prepaid Assets | - | $2,242,000 | $3,890,000 | $1,240,000 |
| Debt | ||||
| Total Debt | $549,000 | $1,085,000 | $674,000 | $637,000 |
| Long Term Debt And Capital Lease Obligation | $0 | $549,000 | $466,000 | $486,000 |
| Current Debt And Capital Lease Obligation | $549,000 | $536,000 | $208,000 | $151,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $5,933,000 | $11,079,000 | $137,576,000 | $70,417,000 |
| Total Non Current Liabilities Net Minority Interest | $12,000 | $549,000 | $130,291,000 | $64,875,000 |
| Other Non Current Liabilities | $12,000 | - | - | - |
| Current Liabilities | $5,921,000 | $10,530,000 | $7,285,000 | $5,542,000 |
| Payables And Accrued Expenses | $2,679,000 | $6,821,000 | $5,414,000 | $3,935,000 |
| Payables | $1,433,000 | $2,968,000 | $3,417,000 | $2,520,000 |
| Accounts Payable | $1,433,000 | $2,968,000 | $3,417,000 | $2,520,000 |
| Equity | ||||
| Common Stock Equity | $56,184,000 | $103,828,000 | $-101,842,000 | $-54,418,000 |
| Total Equity Gross Minority Interest | $56,184,000 | $103,828,000 | $-101,842,000 | $-54,418,000 |
| Stockholders Equity | $56,184,000 | $103,828,000 | $-101,842,000 | $-54,418,000 |
| Retained Earnings | $-214,241,000 | $-154,724,000 | $-102,051,000 | $-57,074,000 |
| Preferred Securities Outside Stock Equity | - | $0 | $129,825,000 | $64,389,000 |
| Other | ||||
| Ordinary Shares Number | $13,673,565 | $13,347,117 | $13,339,417 | $13,339,417 |
| Share Issued | $13,673,565 | $13,347,117 | $13,339,417 | $13,339,417 |
| Tangible Book Value | $56,184,000 | $103,828,000 | $-101,842,000 | $-54,418,000 |
| Invested Capital | $56,184,000 | $103,828,000 | $-101,842,000 | $-54,418,000 |
| Working Capital | $54,918,000 | $102,473,000 | $26,481,000 | $8,081,000 |
| Capital Lease Obligations | $549,000 | $1,085,000 | $674,000 | $637,000 |
| Total Capitalization | $56,184,000 | $103,828,000 | $-101,842,000 | $-54,418,000 |
| Additional Paid In Capital | $270,424,000 | $258,551,000 | $209,000 | $2,655,000 |
| Capital Stock | $1,000 | $1,000 | $0 | $1,000 |
| Common Stock | $1,000 | $1,000 | $0 | $1,000 |
| Long Term Capital Lease Obligation | $0 | $549,000 | $466,000 | $486,000 |
| Current Capital Lease Obligation | $549,000 | $536,000 | $208,000 | $151,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,693,000 | $3,173,000 | $1,663,000 | $1,456,000 |
| Current Accrued Expenses | $1,246,000 | $3,853,000 | $1,997,000 | $1,415,000 |
| Net PPE | $1,005,000 | $1,795,000 | $1,910,000 | $2,047,000 |
| Accumulated Depreciation | $-1,461,000 | $-1,119,000 | $-665,000 | $-248,000 |
| Gross PPE | $2,466,000 | $2,914,000 | $2,575,000 | $2,295,000 |
| Leases | $1,090,000 | $1,090,000 | $1,090,000 | $1,004,000 |
| Other Properties | $1,056,000 | $1,475,000 | $1,184,000 | $1,112,000 |
| Machinery Furniture Equipment | $320,000 | $349,000 | $301,000 | $179,000 |
| Properties | $0 | $0 | $0 | $0 |
Fetched: 2026-07-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-51,874,000 | $-51,169,000 | $-34,792,000 | $-28,087,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-51,828,000 | $-51,117,000 | $-34,546,000 | $-26,953,000 |
| Cash Flow From Continuing Operating Activities | $-51,828,000 | $-51,117,000 | $-34,546,000 | $-26,953,000 |
| Operating Gains Losses | $6,000 | $54,000 | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-46,000 | $-52,000 | $-246,000 | $-1,134,000 |
| Investing Cash Flow | $-46,000 | $15,873,000 | $-246,000 | $-1,134,000 |
| Cash Flow From Continuing Investing Activities | $-46,000 | $15,873,000 | $-246,000 | $-1,134,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $58,907,000 | $53,848,000 | $27,840,000 |
| Financing Cash Flow | $163,000 | $116,129,000 | $53,125,000 | $26,465,000 |
| Cash Flow From Continuing Financing Activities | $163,000 | $116,129,000 | $53,125,000 | $26,465,000 |
| Net Other Financing Charges | $-77,000 | $51,222,000 | $-723,000 | $-1,375,000 |
| Net Common Stock Issuance | $0 | $58,907,000 | $65,000 | $340,000 |
| Common Stock Issuance | $0 | $58,907,000 | $65,000 | $340,000 |
| Net Preferred Stock Issuance | - | $0 | $53,783,000 | $27,500,000 |
| Preferred Stock Issuance | - | $0 | $53,783,000 | $27,500,000 |
| Other | ||||
| Issuance Of Debt | $0 | $6,000,000 | $0 | - |
| Interest Paid Supplemental Data | $0 | $0 | $0 | - |
| End Cash Position | $59,050,000 | $110,761,000 | $29,876,000 | $11,543,000 |
| Beginning Cash Position | $110,761,000 | $29,876,000 | $11,543,000 | $13,165,000 |
| Changes In Cash | $-51,711,000 | $80,885,000 | $18,333,000 | $-1,622,000 |
| Proceeds From Stock Option Exercised | $240,000 | $0 | - | - |
| Net Issuance Payments Of Debt | $0 | $6,000,000 | $0 | - |
| Net Long Term Debt Issuance | $0 | $6,000,000 | $0 | - |
| Long Term Debt Issuance | $0 | $6,000,000 | $0 | - |
| Net Investment Purchase And Sale | $0 | $15,925,000 | $0 | - |
| Sale Of Investment | $0 | $15,925,000 | $0 | - |
| Net PPE Purchase And Sale | $-46,000 | $-52,000 | $-246,000 | $-1,134,000 |
| Purchase Of PPE | $-46,000 | $-52,000 | $-246,000 | $-1,134,000 |
| Change In Working Capital | $-4,780,000 | $-3,952,000 | $6,000 | $2,124,000 |
| Change In Other Current Liabilities | $-524,000 | $-281,000 | $-210,000 | $-194,000 |
| Change In Payables And Accrued Expense | $-4,545,000 | $-5,927,000 | $1,713,000 | $2,650,000 |
| Change In Prepaid Assets | $289,000 | $2,256,000 | $-1,497,000 | $-332,000 |
| Stock Based Compensation | $11,633,000 | $4,530,000 | $199,000 | $48,000 |
| Depreciation Amortization Depletion | $830,000 | $662,000 | $560,000 | $387,000 |
| Depreciation And Amortization | $830,000 | $662,000 | $560,000 | $387,000 |
| Depreciation | $830,000 | $662,000 | $560,000 | $387,000 |
| Gain Loss On Sale Of PPE | $6,000 | $0 | - | - |
| Net Income From Continuing Operations | $-59,517,000 | $-52,673,000 | $-35,311,000 | $-29,512,000 |
| Other Non Cash Items | - | $262,000 | - | - |
| Gain Loss On Investment Securities | - | $54,000 | - | - |
Fetched: 2026-07-15